Shanghai Henlius Biotech, Inc. Class H (2696) Stock Statistics & Valuation Metrics

Shanghai Henlius Biotech, Inc. Class H has a market cap or net worth of HK$21.17B. The enterprise value is HK$15.94B.

Shanghai Henlius Biotech, Inc. Class H has 163,428,540 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shanghai Henlius Biotech, Inc. Class H’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of Shanghai Henlius Biotech, Inc. Class H is ―. Shanghai Henlius Biotech, Inc. Class H’s PEG ratio is ―.

In the last 12 months, Shanghai Henlius Biotech, Inc. Class H had revenue of 5.39B and earned 546.02M in profits. Earnings per share was 1.00.

In the last 12 months, operating cash flow was 966.72M and capital expenditures -556.21M, giving a free cash flow of 410.51M billion.

Shanghai Henlius Biotech, Inc. Class H pays an annual dividend of ―, resulting in a dividend yield of ―

Shanghai Henlius Biotech, Inc. Class H upcoming earnings date is Aug 14, 2025, TBA Not Confirmed.

Shanghai Henlius Biotech, Inc. Class H as a current ratio of ―, with Debt / Equity ratio of ―

In the past 12 months, Shanghai Henlius Biotech, Inc. Class H has paid 23.56M in taxes.

Shanghai Henlius Biotech, Inc. Class H EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

Shanghai Henlius Biotech, Inc. Class H has HK$665.50M in cash and marketable securities with ¥687.91M in debt, giving a net cash position of HK$3.39B billion.

Gross margin is ―, with operating margin of ―, and net profit margin of ―.

The average price target for Shanghai Henlius Biotech, Inc. Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―